Please Wait.....
Report
Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029
Market Report I 2025-01-23 I 525 Pages I MarketsandMarkets
The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.
"The viral vector gene transfer technologies segment accounted for the largest share in 2023."
On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.
"By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market."
The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.
"North America: the largest share of the gene transfer technologies market"
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors acerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US) ) are some of the major players operating in the gene transfer technologies market.
Research Coverage:
This research report categorizes the gene transfer technologiess market product (instruments, consumables, reagents,kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and orther application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as Al and ML) and Challenges (Scalability of production).
- Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.
1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 49
1.3.2 INCLUSIONS & EXCLUSIONS 50
1.3.3 YEARS CONSIDERED 50
1.3.4 CURRENCY CONSIDERED 51
1.4 STAKEHOLDERS 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
2.1.1 SECONDARY DATA 52
2.1.2 PRIMARY DATA 53
2.2 MARKET ESTIMATION METHODOLOGY 55
2.2.1 MARKET ESTIMATION 55
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 57
2.2.3 TOP-DOWN APPROACH 58
2.3 MARKET GROWTH RATE PROJECTION 59
2.4 DATA TRIANGULATION 61
2.5 RESEARCH ASSUMPTIONS 61
2.6 RESEARCH LIMITATIONS 62
2.7 RISK ANALYSIS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 69
4.1 GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW 69
4.2 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023) 70
4.3 GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029 70
4.4 GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
?
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 73
5.2.1.1 Growing demand for personalized medicine and cell & gene therapies 73
5.2.1.2 Increased investments in gene therapy research 74
5.2.1.3 Expanding applications in vaccine development & cancer immunotherapy 75
5.2.2 RESTRAINTS 75
5.2.2.1 High costs of gene delivery systems 75
5.2.3 OPPORTUNITIES 76
5.2.3.1 Advancements in gene editing technologies & nanotechnology 76
5.2.3.2 Integration with digital technologies such as AI & ML 76
5.2.4 CHALLENGES 77
5.2.4.1 Scalability of production 77
5.3 ECOSYSTEM ANALYSIS 78
5.3.1 PRODUCT PROVIDERS 78
5.3.2 END USERS 79
5.3.3 REGULATORY BODIES 79
5.4 TECHNOLOGY ANALYSIS 80
5.4.1 KEY TECHNOLOGIES 80
5.4.1.1 Microinjection 80
5.4.1.2 Electroporation 80
5.4.1.3 Sonoporation 81
5.4.2 COMPLEMENTARY TECHNOLOGIES 81
5.4.2.1 Gene editing technologies 81
5.4.2.2 Bioinformatics and computational tools 81
5.4.3 ADJCENT TECHNOLOGIES 82
5.4.3.1 Nanotechnology and nano-carriers 82
5.5 PRICING ANALYSIS 82
5.5.1 AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER 82
5.5.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION 84
5.6 VALUE CHAIN ANALYSIS 84
5.7 SUPPLY CHAIN ANALYSIS 86
5.8 PATENT ANALYSIS 87
5.9 TRADE ANALYSIS 89
5.9.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330) 89
5.9.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330) 90
5.10 KEY CONFERENCES AND EVENTS, 2024-2025 90
5.11 REGULATORY LANDSCAPE 91
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
5.11.2 REGULATORY FRAMEWORK 93
5.11.2.1 North America 93
5.11.2.2 Europe 94
5.11.2.3 Asia Pacific 94
5.11.2.4 Rest of the World 95
5.12 PORTER'S FIVE FORCES ANALYSIS 96
5.12.1 THREAT OF NEW ENTRANTS 97
5.12.2 THREAT OF SUBSTITUTES 97
5.12.3 BARGAINING POWER OF BUYERS 97
5.12.4 BARGAINING POWER OF SUPPLIERS 97
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 97
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 97
5.13.1 KEY STAKEHOLDERS 98
5.13.2 BUYING CRITERIA 99
5.14 INVESTMENT AND FUNDING SCENARIO 100
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 101
5.16 IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET 102
6 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT 104
6.1 INTRODUCTION 105
6.2 REAGENTS, KITS, AND ASSAYS 105
6.2.1 INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH 105
6.3 CONSUMABLES 109
6.3.1 RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH 109
6.4 INSTRUMENTS 112
6.4.1 INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET 112
6.5 OTHER PRODUCTS 116
7 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE 119
7.1 INTRODUCTION 120
7.2 VIRAL VECTORS 120
7.2.1 RETROVIRUSES 124
7.2.1.1 Lentiviruses 127
7.2.1.1.1 Rising disease incidence to drive market 127
7.2.1.2 Other retroviruses 130
7.2.2 ADENOVIRUSES 133
7.2.2.1 Expansion of vaccination programs to propel market growth 133
7.2.3 ADENO-ASSOCIATED VIRUSES 137
7.2.3.1 Low immunogenicity of AAV vectors to support adoption 137
7.2.4 OTHER VIRAL VECTORS 140
7.3 NON-VIRAL VECTORS 143
7.3.1 CHEMICAL METHODS 147
7.3.2 LIPOSOME-MEDIATED 151
7.3.2.1 High efficiency and compatibility to drive market 151
7.3.3 CALCIUM PHOSPHATE 154
7.3.3.1 Increasing R&D in cell-based therapies to propel market growth 154
7.3.4 DEAE-DEXTRAN 158
7.3.4.1 Simplicity and cost-effectiveness to support adoption 158
7.3.5 CATIONIC POLYMERS 161
7.3.5.1 Advancements in cationic polymer technology to drive market 161
7.3.6 OTHER CHEMICAL METHODS 165
7.4 PHYSICAL METHODS 168
7.4.1 ELECTROPORATION 172
7.4.1.1 Rising demand for effective cell transfection technologies to drive market 172
7.4.2 MICROINJECTION 175
7.4.2.1 High accuracy and control and potential for tailored delivery to drive market 175
7.4.3 GENE GUNS 179
7.4.3.1 High efficiency of gene guns in transfecting various cell types to drive market 179
7.4.4 OTHER PHYSICAL METHODS 182
8 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD 186
8.1 INTRODUCTION 187
8.2 IN VIVO 187
8.2.1 EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS 187
8.3 EX VIVO 191
8.3.1 SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET 191
8.4 IN VITRO 194
8.4.1 DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES. 194
9 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION 198
9.1 INTRODUCTION 199
9.2 THERAPEUTIC APPLICATIONS 199
9.2.1 GENE THERAPY 203
9.2.1.1 Increasing demand for personalized medicine to support market growth 203
9.2.2 CELL THERAPY 206
9.2.2.1 Rising government funding to propel market growth 206
9.2.3 VACCINES 209
9.2.3.1 Rising prevalence of infectious diseases to drive market growth 209
9.2.4 OTHER THERAPEUTIC APPLICATIONS 213
9.3 RESEARCH APPLICATIONS 216
9.3.1 DRUG DISCOVERY & DEVELOPMENT 220
9.3.1.1 Increased funding for gene therapy research to drive market growth 220
9.3.1.2 Cancer 224
9.3.1.2.1 Rising investment in cancer research to drive market 224
9.3.2 INFECTIOUS DISEASES 228
9.3.2.1 Rising incidence of infectious disease to drive market growth 228
9.3.3 GENETIC & NEUROLOGICAL DISORDERS 231
9.3.3.1 Rising burden of disorders to drive market 231
9.3.4 AUTOIMMUNE DISEASES 235
9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions 235
9.3.5 OTHER DISEASES 238
9.3.6 OTHER RESEARCH APPLICATIONS 242
9.4 OTHER APPLICATIONS 245
10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER 249
10.1 INTRODUCTION 250
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 250
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET 250
10.3 ACADEMIC & RESEARCH INSTITUTES 254
10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH 254
10.4 OTHER END USERS 257
11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION 261
11.1 INTRODUCTION 262
11.2 NORTH AMERICA 262
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 263
11.2.2 US 269
11.2.2.1 US to dominate North American market over forecast period 269
11.2.3 CANADA 274
11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth 274
11.3 EUROPE 279
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 280
11.3.2 GERMANY 285
11.3.2.1 Germany to hold largest market share in Europe 285
?
11.3.3 UK 291
11.3.3.1 Increasing government funding to drive market growth 291
11.3.4 FRANCE 296
11.3.4.1 Rising support for genetic research to offer potential growth opportunities 296
11.3.5 ITALY 301
11.3.5.1 Rising R&D and support for gene delivery to drive market 301
11.3.6 SPAIN 306
11.3.6.1 Growing expansion of research centers to stimulate market 306
11.3.7 REST OF EUROPE 311
11.4 ASIA PACIFIC 316
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 316
11.4.2 CHINA 323
11.4.2.1 Increasing R&D expenditure to drive market growth 323
11.4.3 JAPAN 328
11.4.3.1 Rising research into precision medicine to support market growth 328
11.4.4 INDIA 334
11.4.4.1 Strong research base and rising FDI in pharma sector to support market growth 334
11.4.5 SOUTH KOREA 339
11.4.5.1 Alliances & investments in research to drive market 339
11.4.6 AUSTRALIA 344
11.4.6.1 Increasing focus on precision medicine to offer significant growth opportunities 344
11.4.7 REST OF ASIA PACIFIC 349
11.5 LATIN AMERICA 354
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 354
11.5.2 BRAZIL 360
11.5.2.1 Brazil to hold largest market share in LATAM 360
11.5.3 MEXICO 365
11.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth 365
11.5.4 REST OF LATIN AMERICA 370
11.6 MIDDLE EAST 375
11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 375
11.6.2 GCC COUNTRIES 381
11.6.2.1 Saudi Arabia 386
11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market 386
11.6.2.2 UAE 392
11.6.2.2.1 Growing R&D expenditure and infrastructural development to drive market 392
11.6.2.3 Rest of GCC Countries 397
11.6.3 REST OF MIDDLE EAST 403
11.7 AFRICA 408
11.7.1 RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH 408
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 409
12 COMPETITIVE LANDSCAPE 415
12.1 OVERVIEW 415
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 415
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET 415
12.3 REVENUE ANALYSIS 417
12.4 MARKET SHARE ANALYSIS 417
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 419
12.5.1 STARS 419
12.5.2 EMERGING LEADERS 419
12.5.3 PERVASIVE PLAYERS 420
12.5.4 PARTICIPANTS 420
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 421
12.5.5.1 Company footprint 421
12.5.5.2 Region footprint 421
12.5.5.3 Product footprint 422
12.5.5.4 Method footprint 423
12.5.5.5 Application footprint 424
12.5.5.6 End-user footprint 425
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 425
12.6.1 PROGRESSIVE COMPANIES 425
12.6.2 RESPONSIVE COMPANIES 425
12.6.3 DYNAMIC COMPANIES 426
12.6.4 STARTING BLOCKS 426
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 427
12.7 COMPANY VALUATION & FINANCIAL METRICS 428
12.7.1 FINANCIAL METRICS 428
12.7.2 COMPANY VALUATION 428
12.8 BRAND/PRODUCT COMPARISON 429
12.9 COMPETITIVE SCENARIO 430
12.9.1 PRODUCT LAUNCHES 430
12.9.2 DEALS 431
12.9.3 EXPANSIONS 432
?
13 COMPANY PROFILES 433
13.1 KEY PLAYERS 433
13.1.1 THERMO FISHER SCIENTIFIC INC. 433
13.1.1.1 Business overview 433
13.1.1.2 Products/Services/Solutions offered 434
13.1.1.3 Recent developments 441
13.1.1.3.1 Product launches 441
13.1.1.3.2 Expansions 441
13.1.1.4 MnM view 441
13.1.1.4.1 Key strengths 441
13.1.1.4.2 Strategic choices 442
13.1.1.4.3 Weaknesses and competitive threats 442
13.1.2 DANAHER CORPORATION 443
13.1.2.1 Business overview 443
13.1.2.2 Products/Services/Solutions offered 444
13.1.2.3 Recent developments 446
13.1.2.3.1 Product launches 446
13.1.2.3.2 Deals 447
13.1.2.3.3 Expansions 447
13.1.2.4 MnM view 447
13.1.2.4.1 Key strengths 447
13.1.2.4.2 Strategic choices 448
13.1.2.4.3 Weaknesses and competitive threats 448
13.1.3 MERCK KGAA 449
13.1.3.1 Business overview 449
13.1.3.2 Products/Services/Solutions offered 450
13.1.3.3 Recent developments 453
13.1.3.3.1 Deals 453
13.1.3.3.2 Expansions 454
13.1.3.4 MnM view 454
13.1.3.4.1 Key strengths 454
13.1.3.4.2 Strategic choices 454
13.1.3.4.3 Weaknesses and competitive threats 454
13.1.4 BIO-RAD LABORATORIES, INC. 455
13.1.4.1 Business overview 455
13.1.4.2 Products/Services/Solutions offered 456
13.1.5 AGILENT TECHNOLOGIES, INC. 458
13.1.5.1 Business overview 458
13.1.5.2 Products/Services/Solutions offered 459
13.1.5.3 Recent developments 461
13.1.5.3.1 Deals 461
?
13.1.6 REVVITY 462
13.1.6.1 Business overview 462
13.1.6.2 Products/Services/Solutions offered 463
13.1.6.3 Recent developments 465
13.1.6.3.1 Product launches 465
13.1.6.3.2 Deals 465
13.1.7 QIAGEN 466
13.1.7.1 Business overview 466
13.1.7.2 Products/Services/Solutions offered 467
13.1.8 GENSCRIPT 469
13.1.8.1 Business overview 469
13.1.8.2 Products/Services/Solutions offered 470
13.1.8.3 Recent developments 471
13.1.8.3.1 Deals 471
13.1.9 TAKARA BIO INC. 472
13.1.9.1 Business overview 472
13.1.9.2 Products/Services/Solutions offered 473
13.1.9.3 Recent developments 479
13.1.9.3.1 Product launches 479
13.1.9.3.2 Deals 479
13.1.10 PROMEGA CORPORATION 480
13.1.10.1 Business overview 480
13.1.10.2 Products/Services/Solutions offered 480
13.1.11 BIO-TECHNE 482
13.1.11.1 Business overview 482
13.1.11.2 Products/Services/Solutions offered 483
13.1.11.3 Recent developments 485
13.1.11.3.1 Product launches 485
13.1.12 LONZA 486
13.1.12.1 Business overview 486
13.1.12.2 Products/Services/Solutions offered 487
13.1.12.3 Recent developments 489
13.1.12.3.1 Product launches 489
13.1.12.3.2 Deals 489
13.1.13 OXFORD BIOMEDICA PLC 490
13.1.13.1 Business overview 490
13.1.13.2 Products/Services/Solutions offered 491
13.1.13.3 Recent developments 492
13.1.13.3.1 Product launches 492
13.1.13.3.2 Deals 492
13.1.13.3.3 Other developments 493
?
13.1.14 SARTORIUS AG 494
13.1.14.1 Business overview 494
13.1.14.2 Products/Services/Solutions offered 495
13.1.14.3 Recent developments 497
13.1.14.3.1 Product launches 497
13.1.14.3.2 Deals 497
13.1.15 MAXCYTE 498
13.1.15.1 Business overview 498
13.1.15.2 Products/Services/Solutions offered 499
13.1.15.3 Recent developments 500
13.1.15.3.1 Deals 500
13.2 OTHER PLAYERS 503
13.2.1 CELL BIOLABS, INC. 503
13.2.2 GENTARGET INC. 505
13.2.3 ORIGENE TECHNOLOGIES, INC. 507
13.2.4 ALTOGEN BIOSYSTEMS 508
13.2.5 OZ BIOSCIENCES 510
13.2.6 GENECOPOEIA, INC. 512
13.2.7 CREATIVE BIOLABS 513
13.2.8 SYNBIO TECHNOLOGIES LLC 513
13.2.9 SYSTEM BIOSCIENCES, LLC 514
13.2.10 VECTORBUILDER INC. 515
14 APPENDIX 517
14.1 DISCUSSION GUIDE 517
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 521
14.3 CUSTOMIZATION OPTIONS 523
14.4 RELATED REPORTS 523
14.5 AUTHOR DETAILS 524
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 60
TABLE 2 GENE DELIVERY TECHNOLOGIES MARKET: RISK ASSESSMENT ANALYSIS 63
TABLE 3 GENE DELIVERY TECHNOLOGY MARKET: KEY PRODUCT PROVIDERS 78
TABLE 4 GENE DELIVERY TECHNOLOGY MARKET: KEY END USERS 79
TABLE 5 GENE DELIVERY TECHNOLOGY MARKET: REGULATORY BODIES 80
TABLE 6 AVERAGE SELLING PRICE TREND OF GENE DELIVERY REAGENTS/CONSUMABLES, BY KEY PLAYERS, 2021-2023 83
TABLE 7 KEY PATENTS IN GENE DELIVERY TECHNOLOGIES MARKET, 2021-2024 88
TABLE 8 IMPORT VOLUME FOR HS CODE 854330, 2019-2023 (UNITS) 89
TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2019-2023 (UNITS) 90
TABLE 10 GENE DELIVERY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 90
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 15 GENE DELIVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS 96
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 98
TABLE 17 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 105
TABLE 18 GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY REGION,
2022-2029 (USD MILLION) 106
TABLE 19 NORTH AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 20 EUROPE: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 107
TABLE 21 ASIA PACIFIC: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 107
TABLE 22 LATIN AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 23 MIDDLE EAST: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,
BY REGION, 2022-2029 (USD MILLION) 108
TABLE 24 GCC COUNTRIES: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 25 GENE DELIVERY CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION) 109
TABLE 26 NORTH AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 110
TABLE 27 EUROPE: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 110
TABLE 28 ASIA PACIFIC: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 111
TABLE 29 LATIN AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 111
TABLE 30 MIDDLE EAST: GENE DELIVERY CONSUMABLES MARKET, BY REGION,
2022-2029 (USD MILLION) 111
TABLE 31 GCC COUNTRIES: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 112
TABLE 32 GENE DELIVERY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION) 113
TABLE 33 NORTH AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 113
TABLE 34 EUROPE: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 114
TABLE 35 ASIA PACIFIC: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 114
TABLE 36 LATIN AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 115
TABLE 37 MIDDLE EAST: GENE DELIVERY INSTRUMENTS MARKET, BY REGION,
2022-2029 (USD MILLION) 115
TABLE 38 GCC COUNTRIES: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 115
TABLE 39 OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION,
2022-2029 (USD MILLION) 116
TABLE 40 OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 116
TABLE 41 EUROPE: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 117
TABLE 42 ASIA PACIFIC: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 117
TABLE 43 LATIN AMERICA: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 44 MIDDLE EAST: OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION,
2022-2029 (USD MILLION) 118
TABLE 45 GCC COUNTRIES: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 46 GENE DELIVERY TECHNOLOGIES MARKET BY MODE, 2022-2029 (USD MILLION) 120
TABLE 47 VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 121
TABLE 48 VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 121
TABLE 49 NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121
TABLE 50 EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 51 ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 52 LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 53 MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 123
TABLE 54 GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 55 RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 124
TABLE 56 RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 125
TABLE 57 NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 58 EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 59 ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 60 LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 61 MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 126
TABLE 62 GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 63 LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 128
TABLE 64 NORTH AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 65 EUROPE: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 66 ASIA PACIFIC: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 67 LATIN AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 68 MIDDLE EAST: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 129
TABLE 69 GCC COUNTRIES: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 70 OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 130
TABLE 71 NORTH AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 72 EUROPE: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 73 ASIA PACIFIC: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 74 LATIN AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 75 MIDDLE EAST: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 132
TABLE 76 GCC COUNTRIES: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 77 ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 134
TABLE 78 NORTH AMERICA: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 79 EUROPE: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 80 ASIA PACIFIC: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 81 LATIN AMERICA: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 82 MIDDLE EAST: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 136
TABLE 83 GCC COUNTRIES: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 84 AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 137
TABLE 85 NORTH AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 86 EUROPE: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 87 ASIA PACIFIC: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 88 LATIN AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 89 MIDDLE EAST: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 139
TABLE 90 GCC COUNTRIES: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 139
TABLE 91 OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 140
TABLE 92 NORTH AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141
TABLE 93 EUROPE: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141
TABLE 94 ASIA PACIFIC: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 95 LATIN AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 96 MIDDLE EAST: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 142
TABLE 97 GCC COUNTRIES: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 143
TABLE 98 NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 144
TABLE 99 NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 144
TABLE 100 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 144
TABLE 101 EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 102 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 103 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 104 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 146
TABLE 105 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 106 CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 147
TABLE 107 CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 148
TABLE 108 NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 148
TABLE 109 EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 110 ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 111 LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 112 MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 150
TABLE 113 GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 114 LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 151
TABLE 115 NORTH AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 152
TABLE 116 EUROPE: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 152
TABLE 117 ASIA PACIFIC: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 118 LATIN AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 119 MIDDLE EAST: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 120 GCC COUNTRIES: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 121 CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 155
TABLE 122 NORTH AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 155
TABLE 123 EUROPE: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 124 ASIA PACIFIC: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 125 LATIN AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 126 MIDDLE EAST: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 157
TABLE 127 GCC COUNTRIES: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 128 DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 158
TABLE 129 NORTH AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 130 EUROPE: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 131 ASIA PACIFIC: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 132 LATIN AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 133 MIDDLE EAST: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 160
TABLE 134 GCC COUNTRIES: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 135 CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 162
TABLE 136 NORTH AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 137 EUROPE: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 138 ASIA PACIFIC: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 139 LATIN AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 164
TABLE 140 MIDDLE EAST: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 164
TABLE 141 GCC COUNTRIES: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 164
TABLE 142 OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 165
TABLE 143 NORTH AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 144 EUROPE: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 145 ASIA PACIFIC: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 167
TABLE 146 LATIN AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 167
TABLE 147 MIDDLE EAST: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 167
TABLE 148 GCC COUNTRIES: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 149 PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 168
TABLE 150 PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 169
TABLE 151 NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 169
TABLE 152 EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 153 ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 154 LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 155 MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 171
TABLE 156 GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 157 ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 172
TABLE 158 NORTH AMERICA: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 173
TABLE 159 EUROPE: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 173
TABLE 160 ASIA PACIFIC: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 174
TABLE 161 LATIN AMERICA: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 174
TABLE 162 MIDDLE EAST: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 174
TABLE 163 GCC COUNTRIES: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 175
TABLE 164 MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 176
TABLE 165 NORTH AMERICA: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 166 EUROPE: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 167 ASIA PACIFIC: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 168 LATIN AMERICA: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 169 MIDDLE EAST: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION) 178
TABLE 170 GCC COUNTRIES: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 171 GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 179
TABLE 172 NORTH AMERICA: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 173 EUROPE: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 174 ASIA PACIFIC: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 175 LATIN AMERICA: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 176 MIDDLE EAST: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 181
TABLE 177 GCC COUNTRIES: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 182
TABLE 178 OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 183
TABLE 179 NORTH AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 180 EUROPE: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 181 ASIA PACIFIC: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 182 LATIN AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 183 MIDDLE EAST: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY REGION, 2022-2029 (USD MILLION) 185
TABLE 184 GCC COUNTRIES: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 185 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 187
TABLE 186 IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 188
TABLE 187 NORTH AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 188 EUROPE: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 189
TABLE 189 ASIA PACIFIC: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 189
TABLE 190 LATIN AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 191 MIDDLE EAST: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 192 GCC COUNTRIES: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 193 EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 191
TABLE 194 NORTH AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 195 EUROPE: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 192
TABLE 196 ASIA PACIFIC: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 193
TABLE 197 LATIN AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 193
TABLE 198 MIDDLE EAST: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 193
TABLE 199 GCC COUNTRIES: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 200 IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 195
TABLE 201 NORTH AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 202 EUROPE: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 203 ASIA PACIFIC: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 204 LATIN AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 205 MIDDLE EAST: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 206 GCC COUNTRIES: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 207 GENE DELIVERY TECHNOLOGIES MARKET BY APPLICATION,
2022-2029 (USD MILLION) 199
TABLE 208 GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 200
TABLE 209 GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,
BY REGION, 2022-2029 (USD MILLION) 200
TABLE 210 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 211 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 212 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 213 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 214 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 202
TABLE 215 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 202
TABLE 216 GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY REGION, 2022-2029 (USD MILLION) 203
TABLE 217 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 218 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,
BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 219 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,
BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 220 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 221 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,
BY REGION, 2022-2029 (USD MILLION) 205
TABLE 222 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022-2029 (USD MILLION) 206
TABLE 223 GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY REGION,
2022-2029 (USD MILLION) 207
TABLE 224 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 225 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,
BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 226 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,
BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 227 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,
BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 228 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,
BY REGION, 2022-2029 (USD MILLION) 208
TABLE 229 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022-2029 (USD MILLION) 209
TABLE 230 GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY REGION,
2022-2029 (USD MILLION) 210
TABLE 231 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,
BY COUNTRY, 2022-2029 (USD MILLION) 210
TABLE 232 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 233 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,
BY COUNTRY, 2022-2029 (USD MILLION) 211
TABLE 234 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,
BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 235 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,
BY REGION, 2022-2029 (USD MILLION) 212
TABLE 236 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,
BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 237 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 213
TABLE 238 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 214
TABLE 239 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 214
TABLE 240 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 215
TABLE 241 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 215
TABLE 242 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 215
TABLE 243 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 216
TABLE 244 GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 217
TABLE 245 GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2022-2029 (USD MILLION) 217
TABLE 246 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 217
TABLE 247 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 218
TABLE 248 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 218
TABLE 249 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 250 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 219
TABLE 251 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 219
TABLE 252 GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 221
TABLE 253 GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION) 221
TABLE 254 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION) 222
TABLE 255 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION) 222
TABLE 256 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 257 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION) 223
TABLE 258 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION) 223
TABLE 259 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION) 224
TABLE 260 GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY REGION,
2022-2029 (USD MILLION) 225
TABLE 261 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022-2029 (USD MILLION) 225
TABLE 262 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) 226
TABLE 263 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022-2029 (USD MILLION) 226
TABLE 264 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 265 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,
BY REGION, 2022-2029 (USD MILLION) 227
TABLE 266 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022-2029 (USD MILLION) 227
TABLE 267 GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION) 228
TABLE 268 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 269 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 229
TABLE 270 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 230
TABLE 271 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 230
TABLE 272 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION) 230
TABLE 273 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 231
TABLE 274 GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION) 232
TABLE 275 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 232
TABLE 276 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 233
TABLE 277 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 233
TABLE 278 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 234
TABLE 279 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION) 234
TABLE 280 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 234
TABLE 281 GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2022-2029 (USD MILLION) 235
TABLE 282 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 236
TABLE 283 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 236
TABLE 284 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 237
TABLE 285 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 237
TABLE 286 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION) 237
TABLE 287 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 238
TABLE 288 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION) 239
TABLE 289 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 239
TABLE 290 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 240
TABLE 291 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022-2029 (USD MILLION) 240
TABLE 292 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 293 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION) 241
TABLE 294 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 241
TABLE 295 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 242
TABLE 296 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 243
TABLE 297 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 243
TABLE 298 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 299 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 244
TABLE 300 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 244
TABLE 301 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 245
TABLE 302 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 246
TABLE 303 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 246
TABLE 304 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 247
TABLE 305 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 247
TABLE 306 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 248
TABLE 307 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 248
TABLE 308 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 248
TABLE 309 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 250
TABLE 310 GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) 251
TABLE 311 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2022-2029 (USD MILLION) 251
TABLE 312 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 252
TABLE 313 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 252
TABLE 314 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 253
TABLE 315 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) 253
TABLE 316 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2022-2029 (USD MILLION) 253
TABLE 317 GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION) 254
TABLE 318 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 255
TABLE 319 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 255
TABLE 320 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 256
TABLE 321 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 256
TABLE 322 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION) 256
TABLE 323 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 257
TABLE 324 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) 258
TABLE 325 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 258
TABLE 326 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 259
TABLE 327 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 259
TABLE 328 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 260
TABLE 329 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) 260
TABLE 330 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 260
TABLE 331 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,
2022-2029 (USD MILLION) 262
TABLE 332 NORTH AMERICA: KEY MACROINDICATORS 263
TABLE 333 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 264
TABLE 334 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 265
TABLE 335 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 265
TABLE 336 NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 265
TABLE 337 NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 266
TABLE 338 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 266
TABLE 339 NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 266
TABLE 340 NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 267
TABLE 341 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 267
TABLE 342 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 267
TABLE 343 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 268
TABLE 344 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 268
TABLE 345 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 268
TABLE 346 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION) 269
TABLE 347 US: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 270
TABLE 348 US: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 270
TABLE 349 US: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 270
TABLE 350 US: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 351 US: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 352 US: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 271
TABLE 353 US: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 272
TABLE 354 US: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 272
TABLE 355 US: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 272
TABLE 356 US: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 273
TABLE 357 US: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 273
TABLE 358 US: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 273
TABLE 359 US: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 274
TABLE 360 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 275
TABLE 361 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 275
TABLE 362 CANADA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 363 CANADA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 364 CANADA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 365 CANADA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 276
TABLE 366 CANADA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 277
TABLE 367 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 277
TABLE 368 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 277
TABLE 369 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 278
TABLE 370 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 278
TABLE 371 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 278
TABLE 372 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 279
TABLE 373 EUROPE: KEY MACROINDICATORS 280
TABLE 374 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 281
TABLE 375 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 281
TABLE 376 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 281
TABLE 377 EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 378 EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 379 EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 380 EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 283
TABLE 381 EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 283
TABLE 382 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 283
TABLE 383 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 284
TABLE 384 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 385 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 386 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 387 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 285
TABLE 388 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 286
TABLE 389 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 287
TABLE 390 GERMANY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 391 GERMANY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 392 GERMANY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 288
TABLE 393 GERMANY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 288
TABLE 394 GERMANY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 288
TABLE 395 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 289
TABLE 396 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 289
TABLE 397 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 289
TABLE 398 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 290
TABLE 399 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 290
TABLE 400 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 290
TABLE 401 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 291
TABLE 402 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 292
TABLE 403 UK: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 404 UK: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 405 UK: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 293
TABLE 406 UK: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 293
TABLE 407 UK: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 293
TABLE 408 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 294
TABLE 409 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 294
TABLE 410 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 294
TABLE 411 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 295
TABLE 412 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 295
TABLE 413 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 295
TABLE 414 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 296
TABLE 415 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 297
TABLE 416 FRANCE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 417 FRANCE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 418 FRANCE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 298
TABLE 419 FRANCE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 298
TABLE 420 FRANCE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 298
TABLE 421 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 299
TABLE 422 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 299
TABLE 423 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 299
TABLE 424 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 300
TABLE 425 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 300
TABLE 426 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 301
TABLE 427 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 302
TABLE 428 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 302
TABLE 429 ITALY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 302
TABLE 430 ITALY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 303
TABLE 431 ITALY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 303
TABLE 432 ITALY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 303
TABLE 433 ITALY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 304
TABLE 434 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 304
TABLE 435 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 304
TABLE 436 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 305
TABLE 437 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 305
TABLE 438 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 305
TABLE 439 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 306
TABLE 440 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 307
TABLE 441 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 307
TABLE 442 SPAIN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 307
TABLE 443 SPAIN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 308
TABLE 444 SPAIN: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 308
TABLE 445 SPAIN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 308
TABLE 446 SPAIN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 309
TABLE 447 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 309
TABLE 448 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 309
TABLE 449 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 310
TABLE 450 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 310
TABLE 451 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 310
TABLE 452 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 311
TABLE 453 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 312
TABLE 454 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 312
TABLE 455 REST OF EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 312
TABLE 456 REST OF EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 457 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 458 REST OF EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 313
TABLE 459 REST OF EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 314
TABLE 460 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 314
TABLE 461 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 314
TABLE 462 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 315
TABLE 463 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 315
TABLE 464 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 315
TABLE 465 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION) 316
TABLE 466 ASIA PACIFIC: KEY MACROINDICATORS 317
TABLE 467 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 319
TABLE 468 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 319
TABLE 469 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 319
TABLE 470 ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 320
TABLE 471 ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 320
TABLE 472 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 320
TABLE 473 ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 321
TABLE 474 ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 321
TABLE 475 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 321
TABLE 476 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 322
TABLE 477 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 322
TABLE 478 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 322
TABLE 479 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 323
TABLE 480 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 323
TABLE 481 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 324
TABLE 482 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 324
TABLE 483 CHINA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 325
TABLE 484 CHINA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 325
TABLE 485 CHINA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 325
TABLE 486 CHINA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 326
TABLE 487 CHINA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 326
TABLE 488 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 326
TABLE 489 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 327
TABLE 490 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 327
TABLE 491 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 327
TABLE 492 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 328
TABLE 493 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 328
TABLE 494 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 329
TABLE 495 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 330
TABLE 496 JAPAN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 330
TABLE 497 JAPAN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 330
TABLE 498 JAPAN: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 331
TABLE 499 JAPAN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 331
TABLE 500 JAPAN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 331
TABLE 501 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 332
TABLE 502 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 332
TABLE 503 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 332
TABLE 504 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 333
TABLE 505 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 333
TABLE 506 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 334
TABLE 507 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 335
TABLE 508 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 335
TABLE 509 INDIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 335
TABLE 510 INDIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 336
TABLE 511 INDIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 336
TABLE 512 INDIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 336
TABLE 513 INDIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 337
TABLE 514 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 337
TABLE 515 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 337
TABLE 516 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 338
TABLE 517 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 338
TABLE 518 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 338
TABLE 519 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 339
TABLE 520 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 340
TABLE 521 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 340
TABLE 522 SOUTH KOREA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 340
TABLE 523 SOUTH KOREA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 341
TABLE 524 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 341
TABLE 525 SOUTH KOREA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 341
TABLE 526 SOUTH KOREA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 342
TABLE 527 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 342
TABLE 528 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 342
TABLE 529 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 530 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 531 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 343
TABLE 532 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 344
TABLE 533 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 345
TABLE 534 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022-2029 (USD MILLION) 345
TABLE 535 AUSTRALIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 345
TABLE 536 AUSTRALIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 346
TABLE 537 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 346
TABLE 538 AUSTRALIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 346
TABLE 539 AUSTRALIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,
2022-2029 (USD MILLION) 347
TABLE 540 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022-2029 (USD MILLION) 347
TABLE 541 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 347
TABLE 542 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 348
TABLE 543 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION) 348
TABLE 544 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 348
TABLE 545 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022-2029 (USD MILLION) 349
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security